Wells Fargo & Company Biomarin Pharmaceutical Inc Call Options Transaction History

Wells Fargo & Company

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2023 Feb 09, 2024	BUY	$76.22 - $98.51 $1.1 Million - $1.42 Million	14,400 New	14,400 $1.39 Million
Q1 2023 May 12, 2023	BUY	$87.74 - $117.27 $17.8 Million - $23.8 Million	203,200 Added 1016.0%	223,200 $21.7 Million
Q4 2022 Feb 13, 2023	BUY	$80.93 - $108.63 $1.62 Million - $2.17 Million	20,000 New	20,000 $2.07 Million
Q4 2020 Feb 09, 2021	BUY	$72.61 - $90.2 $624,446 - $775,720	8,600 Added 49.71%	25,900 $98,000
Q1 2020 May 14, 2020	BUY	$71.37 - $96.85 $1.23 Million - $1.68 Million	17,300 New	17,300 $167,000

637

177M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.